NFKB1 and Alzheimer disease: In the early stages of AD development, a similar inhibition of NF-κB can attenuate pro-inflammatory microglial activation and mitigate the neurotoxicity of Aβ aggregates, potentially being of benefit to the patients, as discussed in Section 2.2.